Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.21

Margin Of Safety %

32

Put/Call OI Ratio

1.22

EPS Next Q Diff

0.12

EPS Last/This Y

2.03

EPS This/Next Y

0.51

Price

47.02

Target Price

64.21

Analyst Recom

1.76

Performance Q

-7.48

Relative Volume

1.1

Beta

0.5

Ticker: SNY




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15SNY49.770.590.1053633
2025-08-18SNY49.580.880.9336957
2025-08-19SNY50.170.9315.5039395
2025-08-20SNY50.541.206.3345637
2025-08-21SNY50.61.328.8247084
2025-08-22SNY51.351.450.4650404
2025-08-25SNY50.151.440.7850832
2025-08-26SNY50.311.420.8251151
2025-08-27SNY50.111.392.1053332
2025-08-28SNY49.951.382.5753751
2025-08-29SNY49.511.426.3855309
2025-09-02SNY49.581.440.0455799
2025-09-03SNY49.871.300.3858419
2025-09-04SNY45.331.230.5861102
2025-09-05SNY46.481.100.7764297
2025-09-08SNY46.791.180.6163399
2025-09-09SNY47.451.221.6263496
2025-09-10SNY47.171.220.9463620
2025-09-11SNY47.641.210.9364897
2025-09-12SNY47.031.221.8665357
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15SNY49.763.04085.84.54
2025-08-18SNY49.813.04035.34.54
2025-08-19SNY50.193.03828.44.56
2025-08-20SNY50.543.03721.14.56
2025-08-21SNY50.603.03657.94.56
2025-08-22SNY51.353.03811.14.56
2025-08-25SNY50.153.03539.34.56
2025-08-26SNY50.303.03980.24.56
2025-08-27SNY50.113.03929.84.56
2025-08-28SNY49.943.03934.74.56
2025-08-29SNY49.473.03860.34.56
2025-09-02SNY49.603.04064.64.56
2025-09-03SNY49.903.04719.34.56
2025-09-04SNY45.333.03432.84.56
2025-09-05SNY46.503.93194.54.57
2025-09-08SNY46.804.74579.24.58
2025-09-09SNY47.444.74815.14.58
2025-09-10SNY47.174.74473.44.62
2025-09-11SNY47.654.74683.84.62
2025-09-12SNY47.024.74377.94.62
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15SNY0-1.770.13
2025-08-18SNY0-1.700.13
2025-08-19SNY0-1.700.13
2025-08-20SNY0-1.700.13
2025-08-21SNY0-1.700.13
2025-08-22SNY0-1.700.13
2025-08-25SNY0-0.570.13
2025-08-26SNY0-0.570.13
2025-08-27SNY0-0.570.18
2025-08-28SNY0-0.570.18
2025-08-29SNY0-0.570.18
2025-09-02SNY0-0.680.18
2025-09-03SNY0-0.680.18
2025-09-04SNY0-0.680.18
2025-09-05SNY0-0.680.18
2025-09-08SNY0-0.330.18
2025-09-09SNY0-0.330.18
2025-09-10SNY0-0.330.18
2025-09-11SNY0-0.330.21
2025-09-12SNY0-0.330.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.9

Avg. EPS Est. Current Quarter

1.62

Avg. EPS Est. Next Quarter

1.02

Insider Transactions

Institutional Transactions

-0.33

Beta

0.5

Average Sales Estimate Current Quarter

12614

Average Sales Estimate Next Quarter

11284

Fair Value

62.16

Quality Score

93

Growth Score

83

Sentiment Score

57

Actual DrawDown %

21.8

Max Drawdown 5-Year %

-33.5

Target Price

64.21

P/E

11.74

Forward P/E

9.43

PEG

0.91

P/S

2.65

P/B

1.39

P/Free Cash Flow

10.61

EPS

4.01

Average EPS Est. Cur. Y​

4.62

EPS Next Y. (Est.)

5.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.98

Relative Volume

1.1

Return on Equity vs Sector %

-18.5

Return on Equity vs Industry %

-27.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.06

EBIT Estimation

4377.9
Sanofi
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 82878
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
stock quote shares SNY – Sanofi Stock Price stock today
news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025
marketwatch SNY – Sanofi yahoo finance google finance
stock history SNY – Sanofi invest stock market
stock prices SNY premarket after hours
ticker SNY fair value insiders trading